Abstract:Introduction: Immunoglobulin A (IgA) is mostly considered as a non-inflammatory regulator at mucosal areas. However, previous work of our group showed that IgA can also be involved in disease pathology, because it provides a potent stimulus to activate neutrophils after crosslinking of surface CD89 (FcaRI), resulting in chronic inflammation and tissue damage. IgA (auto)antibodies and neutrophils are key players in various diseases, including blistering skin diseases and rheumatoid arthritis. Therefore, we generated an array of anti-CD89 monoclonal antibodies (mAbs) for therapeutic targeting of CD89. The biological activity of newly developed anti-human CD89 mAbs and their potential therapeutic capacity were investigated. Methods: Human neutrophils were isolated from heparinized healthy donor blood. The ability of anti-CD89 mAbs to bind human neutrophils was investigated by flow cytometry. Furthermore, the capacity of these anti-CD89 mAbs to inhibit IgA-mediated phagocytosis, neutrophil extracellular trap (NET) release and migration was studied. To this end, neutrophils were pre-incubated with/without anti-CD89 mAbs after which they were stimulated with IgA-coated beads. The amount of phagocytosed beads, NET release and migrated neutrophils were subsequently analysed. In parallel, chemoattractant leukotriene B4 and lactoferrin (as a measure for degranulation) release were determined. Finally, the therapeutic potential of our prototypic anti-CD89 mAb clone 10E7 was in vivo tested in anti-mouse collagen XVII human IgA-treated transgenic CD89 mice, a preclinical model for autoimmune linear IgA bullous disease (LABD). Results: Our results show that all generated anti-CD89 mAbs bound surface CD89 on neutrophils. Although these anti-CD89 mAbs bind to different epitopes on EC1 of CD89, they all have the capacity to inhibit IgA-mediated phagocytosis, neutrophil extracellular trap (NET) release and neutrophil migration. Moreover, IgA mediated leukotriene B4 and lactoferrin release are decreased in supernatant from anti-CD89 mAbs-treated neutrophils. Finally, anti-CD89 mAb clone 10E7, that was selected based on its selective binding profile on tissue micro arrays, reduced anti-mouse collagen XVII hIgA-induced neutrophil influx in an in vivo linear IgA bullous disease (LABD) mice model. Conclusion: This study clearly indicates that our newly developed anti-CD89 mAbs inhibited IgA-induced neutrophil activation and reduced anti-autoantigen IgA-induced neutrophil influx in vivo, supporting further clinical development for the treatment of LABD.

Inhibition of expression of delayed hypersensitivity by neutralizing monoclonal anti-T-cell fibronectin antibody

Production of a fibronectin-associated lymphokine by cloned mouse T cells

Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

Inhibition of human lymphocyte reactivity by plasma fibronectin in vitro

Low molecular weight heparin inhibits circulating fibrocytes differentiation by modulating neuronal nitric oxide synthase and TGF-β1/Smad pathway.

Enhancement of DTH reaction and inhibition of the expression of class II transplantation antigens by in vivo treatment with antibodies against gamma-interferon.

Influence of fibronectin-containing blood products on lymphocyte reactivity

Protective Effect of an Antibody Against Specific Extracellular Domain of TLR2 on Agonists-Driven Inflammatory and Allergic Response.

A Novel Anti-Tissue Factor Monoclonal Antibody with Anticoagulant Potency Derived from Synthesized Multiple Antigenic Peptide Through Blocking FX Combination with TF

Inflammatory Cytokine-Neutralizing Antibody Treatment Prevented Increases in Follicular Helper T Cells and Follicular Regulatory T Cells in a Mouse Model of Arthritis.

Locally instilled tumor necrosis factor-α antisense oligonucleotide inhibits allergic inflammation via the induction of Tregs.

Formononetin Inhibits Mast Cell Degranulation to Ameliorate Compound 48/80-Induced Pseudoallergic Reactions

Regulation Of The Delayed-Hypersensitivity Reaction In The Lung Reflected As Mononuclear, Mast-Cell And Mucus Cell-Appearance After T-Helper Cell Depletion And Adoptive Transfer

The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface molecules

Inhibition of 2,4-Dinitrofluorobenzene-induced Contact Hypersensitivity Reaction by Antidepressant Drugs

TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism

Expression of the alternatively spliced EIIIB segment of fibronectin

Antibody Activity Induced by Human TGF Fusion Vaccine in Lung Epithelial Cell

Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity

Anticoagulation Inhibition Effects of the Monoclonal Antibody Aginst the Recombinant Human Tissue Factor Pathway Inhibitor 1 on Rhtfpi

Locally instilled tumor necrosis factor α antisense oligonucleotide contributes to inhibition of TH2-driven pulmonary fibrosis via induced CD4+CD25+Foxp3+ regulatory T cells